oham-icmh (Agenda)

Agenda

18th International Conference on Malignancies in HIV/AIDS
October 24-26, 2022
Virtual Meeting: All times are U.S. Eastern Daylight Time

Day 1: OCTOBER 24th
8:30 AM Log In to the Platform
9:00 AM

Opening Remarks and Welcome
Moderator: Robert Yarchoan, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute
9:10 AM

Tribute to Dr. Enrique Mesri
Moderator: Ethel Cesarman, Weill Cornell Medical College
In Memoriam Presentation
Tributes: Omar Coso, Universidad de Buenos Aires, Argentina, and Ethel Cesarman, Weill Cornell Medical College
9:20 AM Tribute Junior Oral
Bone Marrow-Derived Human MSC as Precursors of KS Initiation and Progression Through Endothelial Differentiation and Cytokine Induction After KSHV Infection in a Pro-Angiogenic Environment
Julian Naipauer, Instituto de Fisiología, Biología Molecular y Neurociencias (IFIBYNE), CONICET-Universidad de Buenos Aires, Buenos Aires, Argentina
9:30–11:00 AM

Session 1: Lymphoma and EBV
Moderator: Richard Ambinder, Johns Hopkins University School of Medicine

9:30 AM P1: CART Cell Therapy for HIV-Associated Lymphomas
Stefan Barta, University of Pennsylvania Perelman School of Medicine
10:00 AM O1: Multicentric Castleman Disease in Malawi: Updates From a Prospective Cohort Study and Early Results From a Phase II Safety/Efficacy Study of Rituximab Treatment
Matthew Painschab, University of North Carolina Lineberger Comprehensive Cancer Center
10:15 AM O2: Daratumumab Induces Cell-Mediated Cytotoxicity of Primary Effusion Lymphoma and Can Be Active Against Refractory Disease
Prabha Shrestha, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute
10:30 AM Questions/Discussion/Collaboration
11:00 AM–2:00 PM

Session 2: Anal and Cervical Cancer/HPV
Moderator: Mark Einstein, Rutgers University Medical School

11:00 AM P2: Anal Cancer Epidemiology, Screening, and Treatment of Anal Cancer-Modeling
Ashish Deshmukh, Medical University of South Carolina Hollings Cancer Center
11:30 AM P3: ANCHOR Study
Joel Palefsky, University of California, San Francisco
12:00 PM P4: Anal Screening in People Living With HIV
Megan Clarke, Division of Cancer Epidemiology & Genetics, National Cancer Institute
12:30 PM O3: Risk of Progression From Anal Intraepithelial Neoplasia In Situ to Invasive Anal Cancer in PLWH Compared to HIV Uninfected People
Cameron B. Haas, Division of Cancer Epidemiology & Genetics, National Cancer Institute
12:45 PM O4: Anal Cancer Survival Among Persons Living With HIV in the United States
Jaimie Z. Shing, Division of Cancer Epidemiology & Genetics, National Cancer Institute
1:00 PM O5: Delays in Initiation of Curative Intent Chemoradiation and Patterns of Survivorship Care for Cervical Cancer Patients Living With or Without HIV in Botswana
Jessica George, Donald Bren School of Information and Computer Sciences, University of California, Irvine
1:15 PM O6: HIV-1 Proteins Gp120 and Tat Promote Epithelial-Mesenchymal Transition and Invasiveness of Neoplastic Genital and Oral Epithelial Cells
Sharof M. Tugizov, Department of Medicine, University of California, San Francisco
1:30 PM Questions/Discussion/Collaboration
2:00–3:00 PM Day 1 Poster Viewing

 

Day 2: OCTOBER 25th
8:30 AM Log In to the Platform
9:00 AM

Opening Comments
Geraldina Dominguez, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute
9:15 AM–12:00 PM

Session 3: Kaposi Sarcoma and KSHV
Moderator: Charles Wood, Louisiana State University Health Sciences Center New Orleans

9:15 AM P5: Gammaherpesvirus Modulation of Host Immunity
Blossom Damania, University of North Carolina at Chapel Hill School of Medicine
9:45 AM P6: Novel Agents for KSHV-Associated Diseases
Robert Yarchoan, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute
10:15 AM O7: Antisense-to-Latency Transcript Long Noncoding RNA in Kaposi’s Sarcoma-Associated Herpesvirus Perturbs Host Alternative Splicing Regulation
Yuan Hong, Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville
10:30 AM O8: Bulk and Spatial Transcriptional Analysis Identifies Overlapping and Tissue-Distinct Profiles Between Kaposi Sarcoma Tumors of the Skin and Gastrointestinal Tract
Joseph M. Ziegelbauer, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute
10:45 AM O9: Whole Genome Sequencing of Kaposi’s Sarcoma-Associated Herpesvirus from Patients of Diverse Ethnicities Reveals Variation Across the Genome, Recombination, and Infection With Multiple Variants
Vickie A. Marshall, Viral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research
11:00 AM O10: Kaposi Sarcoma Patient-Derived Xenografts as a Preclinical Model for Evaluation of Novel Therapeutic Strategies
Xiaofan Li, HIV and AIDS Malignancy Branch, National Cancer Institute
11:15 AM O11: Immunization of Mice With Virus-Like Vesicles of Kaposi Sarcoma-Associated Herpesvirus Reveals a Role for Antibodies Targeting ORF4 in Activating Complement-Mediated Neutralization
Ting-Ting Wu, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles
11:30 AM Questions/Discussion/Collaboration
12:00–1:30 PM

Session 4: Junior Investigator Research in Progress Session
Moderators: Satish Gopal, Center for Global Health, National Cancer Institute, and Warren Phipps, Fred Hutchinson Cancer Research Center

12:00 PM O12: K5 Undergoes Caspase Cleavage and Protects KSHV-Infected Cells From Caspase-Mediated Cell Death
Yana Astter, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute
12:10 PM O13: WT1 Oncogenic Isoforms Are Upregulated by KSHV vFLIP: A Potential New Immunotherapeutic Intervention for Kaposi Sarcoma
Ayana Morales, Department of Medicine, Weill Cornell Medicine
12:20 PM O14: Extracellular Vesicles as Biomarkers for AIDS-Associated Non-Hodgkin Lymphoma Risk
Laura E. Martínez, UCLA AIDS Institute and David Geffen School of Medicine, University of California, Los Angeles
12:30 PM O15: More Frequent Bone Marrow Involvement in HIV Positive vs. Negative Classical Hodgkin Lymphoma Patients in Johannesburg, South Africa: A Prospective Study
Samantha L. Vogt, Department of Medicine, Johns Hopkins School of Medicine
12:40 PM O16: Advanced Biological Aging in Non-AIDS-Defining Cancer Patients Living With HIV
Brittney L. Dickey, Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute
12:50 PM O17: Penile Human Papillomavirus (HPV) in Men Who Have Sex With Men (MSM) and Transgender Women (TGW) From Buenos Aires: Initial Experience and Sample Collection Set
Diego Salusso, Fundación Huésped, Buenos Aires, Argentina
1:00 PM O18: Disparities in Trends in Cancer Incidence Rates Among Persons Living With HIV During 2001–2016 in the HIV/AIDS Cancer Match Study
Qianlai Luo, National Cancer Institute
1:10 PM O19: Risk of Hepatocellular Carcinoma Among People Living With HIV in the United States
Jennifer K. McGee-Avila, Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute
1:20 PM O20: Decreasing Incidence of Squamous Cell Carcinoma of the Conjunctiva in People Living With HIV—the South African HIV Cancer Match Study (2004–2014)
Carole Metekoua, National Health Laboratory Service, Johannesburg, South Africa
1:30 PM Questions/Discussion/Collaboration
2:00–3:00 PM Day 2 Poster Viewing

 

Day 3: OCTOBER 26th
8:30 AM Log In to the Platform
8:50 AM

Opening Comments
9:00–11:30 AM

Session 5: Epidemiology
Moderator: Eric Engels, Division of Cancer Epidemiology & Genetics, National Cancer Institute

9:00 AM P7: KS and KSHV in the South
Sheena Knights, The University of Texas Southwestern Medical Center
9:30 AM P8: Life-Years Lost to Cancer
Qianlai Luo, Division of Cancer Epidemiology & Genetics, National Cancer Institute
9:45 AM P9: SAM Study to Understand Cancer Trends and Survival
Mazvita Sengayi-Muchengeti, National Cancer Registry, Johannesburg, South Africa
10:15 AM O21: Age and Cancer Incidence in 5.2 Million People Living With HIV in South Africa
Yann Ruffieux, University of Bern, Switzerland
10:30 AM O22: Cancer Treatment Inequities in People Living With HIV in the United States
Jennifer K. McGee-Avila, Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute
10:45 AM O23: Adjuvant Chemotherapy for NSCLC in Patients Living With HIV: A Simulation Study
Keith Sigel, Icahn School of Medicine at Mount Sinai
11:00 AM Questions/Discussion/Collaboration
11:30 AM–1:30 PM

Session 6: Clinical and Translational Studies of HIV and Cancer
Moderators: Richard Little, Clinical Investigations Branch, National Cancer Institute, and Susan Krown, Memorial Sloan Kettering Cancer Center

11:30 AM O24: Altered Tumor Mutational Burden and Immune Microenvironment of Non-Small Cell Lung Carcinoma Among People With HIV
Brinda Emu, Yale University School of Medicine
11:45 AM O25: HIV and the Incidence of Conjunctival Squamous Cell Carcinoma in South Africa: A 25-Year Analysis of the National Cancer Registry (1994–2018)
Kelsey Stuart, NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
12:00 PM O26: Microbiome Changes in Oral and Anal Samples From HIV-Exposed iIndividuals
E. Lacunza, CINIBA, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, Argentina
12:15 PM O27: Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma With or Without Other KSHV-Associated Diseases
Ramya Ramaswami, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute
12:30 PM O28: Whole Exome Sequencing Reveals Sparse Mutational Landscape in Kaposi Sarcoma
Warren Phipps, Fred Hutchinson Cancer Research Center
12:45 PM O29: High-Resolution Antibody Epitope Profiling Reveals Differences Between Symptomatic and Asymptomatic KSHV Infection
Sydney J. Bennett, School of Biological Sciences, University of Nebraska-Lincoln
1:00 PM Questions/Discussion/Collaboration
1:30–2:30 PM Day 3 Poster Viewing
2:30 PM Concluding Remarks